Krystal Biotech, (NASDAQ:KRYS) changed 1.81% to recent value of $53.45. The stock transacted 140470 shares during most recent day however it has an average volume of 155.21K shares. It spotted trading -20.04% off 52-week high price. On the other end, the stock has been noted 188.92% away from the low price over the last 52-weeks.
On Feb. 25, 2020, Krystal Biotech, (NASDAQ:KRYS) a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from skin diseases, declared the appointment of Kathryn Romano as chief accounting officer, based in its headquarters in Pittsburgh, PA. Krystal also announced that Tony Riley has resigned as chief financial officer, effective Feb. 22, 2020.
As our corporate needs continue to evolve, particularly as we develop our research, clinical manufacturing and regulatory footprint in Pittsburgh, Kate brings important financial leadership experience to manage the growth of our company, said Krish S. Krishnan, chairman and chief executive officer of Krystal. It is my pleasure to welcome Kate to Krystal’s senior management team. We thank Tony for his contributions over the years and wish him the very best moving forward.
Ms. Kathryn Romano was most recently corporate controller at CNX Resources Corporation. Prior to joining CNX, Ms. Romano was the corporate controller of Rice Energy from January 2013 until the company was acquired by EQT in November 2017, staying on to assist the company through the transition until March 2018. Prior to joining Rice Energy, she worked in a variety of accounting and auditing roles at Black Box Corporation and Deloitte. Ms. Romano is a Certified Public Accountant and holds a bachelor’s degree in accounting from Penn State University.
About Krystal Biotech
Krystal Biotech (NASDAQ: KRYS) is a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from dermatological diseases.
The company has 17.00M of outstanding shares and 11.58M shares were floated in the market. According to the most recent quarter its current ratio was 54.9 that represents company’s ability to meet its current financial obligations. The price moved ahead of -9.09% from the mean of 20 days, -6.44% from mean of 50 days SMA and performed 15.16% from mean of 200 days price. Company’s performance for the week was -9.83%, -3.80% for month and YTD performance remained -3.49%.